Oak Hill Bio Launches With Pipeline and Senior Leadership Fr

New Company Committed to Developing Life-Changing Medicines for Extremely Preterm Infants and Patients Suffering from Rare Autoimmune Diseases Pipeline Includes Two Programs with Phase 2 Proof-of-Concept

Related Keywords

United States , United Kingdom , Norman Barton , Smithkline Beecham , Daniel Curran , Hill Bio , Mark Mchale , Josh Distler , Chris Railey , Glaxosmithkline Plc , Company Committed To Developing Life , Division Of Neonatology , Global Program , De Shaw Co , Olive View Medical Center , Astrazeneca , Takeda Pharmaceutical Company Limited , Global Program Leader , Aslan Pharmaceuticals , New Company Committed , Developing Life Changing Medicines , Extremely Preterm Infants , Patients Suffering , Rare Autoimmune , Includes Two Programs , Concept Data , Rare Diseases , Significant Unmet , Oak Hill , Victoria Niklas , Chief Medical Officer , Rare Genetics Hematology Therapeutic Area Unit , Chief Financial Officer , Oak Hill Bio , Global Program Lead , Quantitative Equity , Athanor Capital , Global Private Investing , Chief Operating Officer , Chief Scientific Officer , Chief Development Officer , Nemours Children , Division Chief , Medical Director , View Medical , Marie Fields , Investor Relations , Bridge Communications , Hill , Aunches , Ith , Pipeline , Senior , Leadership , Rom , Makeda ,